<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23390538</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice.</ArticleTitle><Pagination><StartPage>e55536</StartPage><MedlinePgn>e55536</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e55536</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0055536</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human enterovirus 71 (HEV71) is one of the major pathogen responsible for hand, foot and mouth disease (HFMD). Currently no effective vaccine or antiviral drugs are available. Like poliovirus, EV71 is transmitted mainly by the feco-oral route. To date the majority of the studied EV71 vaccine candidates are administered parenterally. Injectable vaccines induce good systemic immunity but mucosal responses are often unsatisfactory, whereas mucosal vaccines provide both systemic and mucosal immunity. Therefore, oral immunization appears to be an attractive alternative to parenteral immunization.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">In this report, we studied the efficacy of an orally administered vaccine candidate developed using recombinant baculovirus displaying VP1 (Bac-VP1) in a murine model. Gastrointestinal delivery of Bac-VP1 significantly induced VP1-specific humoral (IgG) and mucosal (IgA) immune responses. Further, we studied the efficacy of the Bac-VP1 associated with bilosomes and observed that the Bac-VP1 associated with bilosomes elicited significantly higher immune responses compared to bilosomes non-associated with Bac-VP1. However, mice immunized subcutaneously with live Bac-VP1 had significantly enhanced VP1 specific serum IgG levels and higher neutralizing antibody titers compared with mice orally immunized with live Bac-VP1 alone or associated with bilosomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Bilosomes have been shown to possess inherent adjuvant properties when associated with antigen. Therefore Bac-VP1 with bilosomes could be a promising oral vaccine candidate against EV71 infections. Thus, Bac-VP1 loaded bilosomes may provide a needle free, painless approach for immunization against EV71, thereby increasing patient compliance and consequently increasing vaccination coverage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Premanand</LastName><ForeName>Balraj</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabakaran</LastName><ForeName>Mookkan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kiener</LastName><ForeName>Tanja K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Kwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015678" MajorTopicYN="N">Viral Structural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23390538</ArticleId><ArticleId IdType="pmc">PMC3563597</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0055536</ArticleId><ArticleId IdType="pii">PONE-D-12-20670</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC (2012) Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2: 199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang LW, Phoon MC, Wu Y, Cutter J, James L, et al. (2011) The changing seroepidemiology of enterovirus 71 infection among children and adolescents in Singapore. BMC Infect Dis 11: 270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198955</ArticleId><ArticleId IdType="pubmed">21988931</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, et al. (1989) The Cell Attachment Site on Foot-and-Mouth Disease Virus Includes the Amino Acid Sequence RGD (Arginine-Glycine-Aspartic Acid). J. Gen. Virol 70: 625&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">2543752</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff E, Thiel HJ, Beck E, Strohmaier K, Schaller H (1988) Analysis of neutralizing epitopes on foot-and-mouth disease virus. J. Virol 62: 2033&#x2013;2040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253288</ArticleId><ArticleId IdType="pubmed">2835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueckert RR (1990) Picornaviruses and their replication. In: Fields, B.N., Knipe, D.M. (Eds.). Virology Lippincott-Raven, New York 507.</Citation></Reference><Reference><Citation>Premanand B, Kiener TK, Meng T, Tan YR, Jia Q, et al. (2012) Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antiviral Res 95(3): 311&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22691220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolpe AB (2012) Kiener TK (2012) Grotenbreg GM, Kwang J (2012) Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res 168(1&#x2013;2): 64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22728446</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Mao C, Ma S, Wang X, Sun Z, et al. (2009) Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: 1126&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">19799860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CS, Cardosa MJ (2007) High-titred neutralizing antibodies to human enterovirus preferentially bind to the N-terminal portion of the capsid proteinVP1. Arch. Virol 152: 1069&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">17318736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: 7444&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogra PL, Faden H, Welliver RC (2001) Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev 14: 430&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88982</ArticleId><ArticleId IdType="pubmed">11292646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8: 1671&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotter H, R&#xfc;ssmann H, Heesemann J, Tannich E (2008) Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis. Int J Med Microbiol 298: 79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17900982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann BJ, Burkholder BV, Lockhart LA (1997) Protection in a gerbil model of amebiasis by oral immunization with Salmonella ex-pressing the galactose/N-acetyl D-galactosamine inhibitable lectin of Entamoeba histolytica. Vaccine 15: 659&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9178467</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng XJ, Tachibana H (2001) Protection of hamsters from amebic liver abscess formation by immunization with the 150- and 170-kDa surface antigens of Entamoeba histolytica. Parasitol Res 87: 126&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11206109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotter H, R&#xfc;ssmann H, Heesemann J, Tannich E (2004) Oral vac-cina-tion with recombinant Yersinia enterocolitica expressing hybrid type III proteins protects gerbils from amebic liver ab-scess. Infect Immun 72: 7318&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC529123</ArticleId><ArticleId IdType="pubmed">15557659</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji I, Aizaki H, Tani H, Ishii K, Chiba T, et al. (1997) Efficient gene transfer into various mammalian cells, including non-hepatic cells, by bac-ulovirus vectors. J Gen Virol. 78: 2657&#x2013;2664.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349488</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J (2010) Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol 84: 3201&#x2013;3209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838147</ArticleId><ArticleId IdType="pubmed">20071572</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauletti GM, Gangwar S, Knipp GT, Nerurkar MM, Okumu FW, et al. (1996) Structural requirements for intestinal absorption of peptide drugs. J Con Rel 41: 3&#x2013;17.</Citation></Reference><Reference><Citation>Shalaby WSW (1995) Development of oral vaccines to stimulate mucosal and systemic immunity:barriers and novel strategies. Clin Immunol Immunopath 74: 127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">7828366</ArticleId></ArticleIdList></Reference><Reference><Citation>Manna JFS, Ferro VA, Mullen AB, Tetley L, Mullen M, et al. (2004) Optimization of a lipid based oral delivery system containing A/Panama influenza hemagglutinin. Vaccine 22: 2425&#x2013;2429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15193405</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaka M, Yasuda Y, Mizokami M, Kozuka S, Taniguchi T, et al. (2001) Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant cholera toxin B subunit as an adjuvant. Vaccine 19: 1460&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163669</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Prabakaran D, Jain S, Mishra V, Jaganathan KS, et al. (2004) Cholera toxin B subunit conjugate bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm 278: 379&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">15196642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JFS, Scales HE, Shakir E, Alexander JA, Carter KC, et al. (2006) Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38: 90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">16414269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry DW, White JC, Goldman ID (1978) Rapid separation of low molecular weight solutes from liopsomes without dilution. Anal Biochem 90: 809&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">727510</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBarre DD, Lowy RJ (2001) Improvements in methods for calculating virus titer estimating TCID50 and plaque assays. J. Virol. Methods 96: 107&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445142</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarthi D, Ananda Rao K, Robinson R, Srinivasan VA (2004) Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine. Biologicals 32: 153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15536046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueda P, Fominaya J, Langeveld JPM, Bruschke C, Vela C, et al. (2000) Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 19: 726&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">11115693</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kolpe AB, Kiener TK, Vincent TK, Kwang J (2011) Display of VP1 on the surface of Baculovirus and Its Immunogenicity against Heterologous Human enterovirus 71 Strains in Mice. PLoS One 6: e21757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly DR, Miller LK, Luckow VA (1992) Baculovirus expression vectors: a laboratory manual, p.60&#x2013;61. W. H. Freeman and Company, New York, NY.</Citation></Reference><Reference><Citation>Conacher M, Alexander J, Brewer JM (2001) Oral immunization with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19: 2965&#x2013;2974.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282208</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer JM, Roberts CW, Stimson WH, Alexander J (1995) Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay. Vaccine 13: 1441&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8578823</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed MS, Kwang J (2011) Oral vaccination of baculovirus-expressed VP28 displays enhanced protection against White Spot Syndrome Virus in Penaeus monodon. PLoS One 6(11): e26428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206036</ArticleId><ArticleId IdType="pubmed">22069450</ArticleId></ArticleIdList></Reference><Reference><Citation>Watarai S, Han M, Tana M, Kodama H (1998) Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes. J Vet Med Sci 60: 1047&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">9795911</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (2004) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 53: 1&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ed C Lavelle, D T O&#x2019;Hagan (2006) Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv 3: 747&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">17076597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kost TA, Condreay JP (2002) Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 20: 173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906750</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani,H, Limn CK, Yap CC, Onishi M, Nozaki M, et al. (2003) In vitro and in vivo gene delivery by recombinant baculoviruses. J Virol 77: 9799&#x2013;9808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC224587</ArticleId><ArticleId IdType="pubmed">12941888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnunen K, Kalesnykas G, Mahonen AJ, Laidinen S, Holma L, et al. (2009) Baculovirus is an efficient vector for the transduction of the eye: comparison of baculovirusand adenovirus-mediated intravitreal vascular endothelial growth factor D gene transfer in the rabbit eye. J Gene Med 11: 382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19263462</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldoveanu Z, Novak M, Juanh W-Q, Gilley RM, Staas JK, et al. (1993) Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 167: 84&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8418185</ArticleId></ArticleIdList></Reference><Reference><Citation>Allaoui-Attarki K, Fattal E, Pecquet S, Trolle S, Chachaty E, et al. (1998) Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres. Vaccine 16: 685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562687</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JCS, et al. (1998) Protective immunity by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72: 5757&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110376</ArticleId><ArticleId IdType="pubmed">9621034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazi HO, Potter CW, Smith TL, Jennings R (1995) Comparative antibody responses and protection in mice immunized by oral or parenteral routes with influenza virus subunit antigens in aqeous form or incorporated into ISCOMs. J Med Microbiol 42: 53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">7739026</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloy KJ, Donachie AM, Mowat AM (1995) Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMs. Eur J Immunol 25: 2835&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">7589080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, et al. (2009) Lipid vesicle size of an oral influenza delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27: 3643&#x2013;3649.</Citation><ArticleIdList><ArticleId IdType="pubmed">19464545</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjia ST, zu Altenschildesche GM, Doerfler W (1983) Autographa californica nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass culture of mammalian cells.Virology. 125: 107&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">6402854</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss R, Huser A, Ni S, Tuve S, Kiviat N, et al. (2007) Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium circumsporozoite protein Mol Ther. 15: 193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">17164791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YC, Tsai CT, Chung YC, Ku JT, Hsu JT (2003) Generation of chimeric baculovirus with histidine-tags displayed on the envelope and its purification using immobilized metal affinity chromatography. Enzyme Microb Technol 33: 445&#x2013;452.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>